Abstract
Pfizer is the world's largest ethical pharmaceutical company, its main areas
in human health being cardiovascular, central nervous system disorders and
infectious diseases. This report provides a full review of the company's
activities together with sales forecasts for key products to 2010.
Headquartered in New York, Pfizer has been the world's largest research-based
Pharmaceutical company since it stole Merck & Co's crown in 1998. The
subsequent acquisition of Warner-Lambert (and with it Agouron) in June 2000
and the merger with Pharmacia in April 2003 (which included the former
Monsanto division, GD Searle) cemented this position and it looks unlikely to
be toppled in the near future.
Pfizer has a broad portfolio, with strengths in the areas of cardiovascular
disease, central nervous system disorders, inflammatory disease, metabolic
disorders, infectious diseases and oncology.
Employing around 115,000 people worldwide, it has more than 100 overseas
subsidiaries and operations in around 150 countries.
Pfizer believes it has one of the broadest product portfolios of all the major
pharmaceutical companies. In 2004, Pfizer set an industry record with ten of
its products (including Celebrex) generating revenues of more than US$1
billion each; 2005 saw a decline in sales of Neurontin and the voluntary
withdrawal of Bextra, reducing this total to eight.
During 2005, Pfizer filed an NDA with the FDA for marketing approval of
Exubera (inhaled insulin) and it was finally approved in the US in
January 2006. Pfizer submitted a revised label to the FDA for the add-on
epilepsy indication for Lyrica, which was approved in 2004 for the
treatment of diabetic peripheral neuropathy and post-herpetic neuralgia.
Pfizer also submitted several important sNDAs for new indications for existing
products including the cancer agent, Aromasin, the novel antibiotic,
Zyvox, and the antifungal, Vfend. Pfizer's medicine depo-subQ
provera 104 received FDA approval for contraception and endometriosis.
Table of Contents
Principal Operating Results
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Financial Performance 2005
- Sales and Market Position
- Income
- Operating Income By Business Area
- Operating Income By Business Area
- Sales, Costs and Operating Income
- Expenditure
- R&D Expenditure & Capital Expenditure
- Capital Expenditure
- Capital Expenditure By Business Area
- Capital Expenditure By Business Area
- R&D Expenditure
- Divisional Performance
- Sales By Business Area
- Sales By Business Area
- Identifiable Assets By Business Area
- Geographic Performance
- Sales By Origin
- Sales By Origin
- Long-Lived Assets By Geographical Area
- US Region
- Japan Region
- Other Region
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- New Licensing Agreements and Acquisitions
- Production
- Employees
- Employees and Productivity
- Product / R&D Overview
- Key Products
- Key Patent Expiry Dates
- Recent Product Approvals
- R&D Strategy
- Key R&D Projects
- Discontinued R&D Projects
- Capravirine
- CDP-870
- CP-644,673 (P57)
- Edotecarin (J-107088)
- Sumanirole
- Sales Forecast
- Sales of Current Top Ten Products (2000A-2010E)
- Conclusions / Outlook
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Sales By Therapeutic Area/Major Products
- Sales By Therapeutic Area
- Top Selling Products, 2005
- R&D Pipeline
- Cardiovascular / Metabolism - Products
- Breakdown of Cardiovascular/Metabolic Product Sales
- Major Launched Products
- Inspra
- Mode of Action
- Key Markets/Indications/Formulations
- Competitor Products
- Sales Forecast
- Clinical Trial Results
- Lipitor
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Combinations
- Competitor Products
- Generic Competition/Lawsuits
- Sales Forecast
- Lipitor Sales (2000A-2010E)
- Clinical Trial Results
- Clinical Trial Results - TNT Trial
- Clinical Trial Results - Alzheimer's Disease
- Norvasc
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Competitor Products
- Lawsuits/Generic Competition
- Sales Forecast
- Norvasc Sales (2000A-2010E)
- Cardiovascular / Metabolism - R&D
- ETC-216
- ETC-588
- ETC-642
- NOX-B11
- Torcetrapib (CP-529,414)
- Cardiovascular / Metabolism - Summary
- Growth Potential
- Limiting Factors
- Central Nervous System - Products
- Breakdown of CNS Sales
- Major Launched Products
- Aricept
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- New Indications
- New Formulations
- Competitor Products
- Generic Competition
- Sales Forecast
- Aricept Sales (2000A-2010E)
- Clinical Trial Results - Continuous Treatment Study
- Clinical Trial Results - Long-Term Studies
- Clinical Trial Results - Vascular Dementia
- Clinical Trial Results - Multiple Sclerosis
- Clinical Trial Results - Other Memory-Related Conditions
- Geodon/Zeldox
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Safety Issues/Product Labelling
- Sales Forecast
- Geodon/Zeldox Sales (2000A-2010E)
- Lyrica (pregabalin, CI-1008)
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Safety Issues
- Clinical Trial Results - Epilepsy
- Clinical Trial Results - Anxiety
- Clinical Trial Results - Neuropathic Pain
- Neurontin
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Lawsuits/Generic Competition
- Lawsuits/Generic Competition - Tablet Formulations
- Sales Forecast
- Neurontin Sales (2000A-2010E)
- Relpax
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Competitor Products
- Sales Forecast
- Relpax Sales (2000A-2010E)
- Zoloft
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Competitor Products
- Lawsuits/Generic Competition
- Safety Issues
- Sales Forecast
- Zoloft Sales (2000A-2010E)
- Clinical Trial Results - Generalised Anxiety Disorder
- Clinical Trial Results - AD and Major Depression
- Clinical Trial Results - Panic Disorder
- Clinical Trial Results - MDD/OCD
- Clinical Trial Results - Binge Eating Disorder
- Central Nervous System - R&D
- Champix
- Indiplon
- Champix
- NGD 96-3
- Central Nervous System - Summary
- Growth Potential
- Limiting Factors
- Infectious and Respiratory - Products
- Breakdown of Infectious Disease/Respiratory Sales
- Major Launched Products
- Diflucan
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Donation Programmes
- Competitor Products
- Generic Competition
- Sales Forecast
- Diflucan Sales (2000A-2010E)
- Eraxis
- Zithromax
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Zithromax SR/Zmax
- Further Development
- Sales Forecast
- Zithromax Sales (2000A-2010E)
- Zyvox/Zyvoxa
- Mode of Action
- Key Markets/Indications/Formulations
- Infectious and Respiratory - R&D
- Maraviroc
- Tipranavir
- Zeven
- Infectious and Respiratory - Summary
- Growth Potential
- Limiting Factors
- Arthritis and Pain - Products
- Breakdown of Arthritis/Pain Sales
- Major Launched Products
- Bextra
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Safety Issues
- Celebrex/Celebra
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Competitor Products
- Safety Issues
- Sales Forecast
- Celebrex Sales (2000A-2010E)
- Clinical Trial Results
- Clinical Trial Results - Ankylosing Spondylitis
- Clinical Trial Results - Lung Cancer
- Clinical Trial Results - Celecoxib in Ocular Herpes
- Dynastat
- Mode of Action
- Key Markets/Indications/Formulations
- Further Development
- Clinical Trial Results
- Arthritis and Pain - R&D
- Arthritis and Pain - Summary
- Growth Potential
- Limiting Factors
- Urology - Products
- Breakdown of Urology Sales
- Major Launched Products
- Viagra/Revatio
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Lawsuits/Generic Competition/Patents
- Safety Issues
- Sales Forecast
- Viagra Sales (2000A-2010E)
- Clinical Trial Results
- Clinical Trial Results - Patients with Cardiac Conditions
- Clinical Trial Results - Pulmonary Hypertension
- Urology - Summary
- Growth Potential
- Limiting Factors
- Oncology - Products
- Breakdown of Oncology Sales
- Major Launched Products
- Sutent
- Oncology - R&D
- AG-014699
- CP-547,632
- CP-868,596
- CP-724,714
- PD0325901
- PF-3512676
- Ticilimumab (CP-675,206)
- Oncology - Summary
- Growth Potential
- Limiting Factors
- Ophthalmology - Products
- Breakdown of Ophthalmology Sales
- Major Launched Products
- Xalatan/Xalcom/Xalacom
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Xalcom/Xalacom
- Lawsuits/Generic Competition
- Sales Forecast
- Xalatan/Xalcom Sales (2000A-2010E)
- Ophthalmology - R&D
- Ophthalmology - Summary
- Endocrine Disorders - Products
- Breakdown of Endocrine Sales
- Major Launched Products
- Exubera
- Key Markets/Indications
- Competitor Products
- Clinical Trial Results - Type I Diabetes
- Clinical Trial Results - Type II Diabetes
- Genotropin
- Mode of Action
- Sales
- Key Markets
- Key indications
- Delivery systems/Formulations
- Competitor Products
- Generic Competition
- Safety Issues
- Sales Forecast
- Genotropin Sales (2000A-2010E)
- Endocrine Disorders - R&D
- Endocrine Disorders - Summary
- Women's Healthcare - Products
- Women's Healthcare - R&D
- Other - Products
- Breakdown of Other Product Sales
- Major Launched Products
- Zyrtec/Reactine
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Competitor Products
- Generic Competition
- Sales Forecast
- Zyrtec Sales (2000A-2010E)
- Other - R&D
APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2005
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 2 - KEY CORPORATE EVENTS
- Merger with Pharmacia
- Key Events
APPENDIX 3 - KEY AGREEMENTS
- Launched Products
- Pipeline Products
- Strategic Investments
- Abgenix Inc
- December 1997
- 28th February 2000
- 9th January 2001
- 16th July 2003
- 30th January 2004
- ActivX Biosciences Inc
- 10th July 2003
- 9th February 2005
- 14th March 2005
- Akzo Nobel
- 2nd June 2003
- 20th October 2003
- 26th June 2005
- Allergan
- 22nd July 1998
- 27th July 1998
- 24th October 2002
- ALZA Corporation
- 9th July 1997
- 29th January 2003
- Astellas Pharma Inc
- 19th January 1998
- 13th July 1998
- 28th March 2001
- 31st May 2004
- Astex Therapeutics
- Baxter International
- 14th January 1998
- 23rd March 2006
- Boehringer Ingelheim
- 28th January 2000
- 11th April 2001
- Chromos Molecular Systems
- Coley Pharmaceutical Group Inc
- 24th March 2005
- 16th May 2005
- Crucell
- Daiichi Sankyo Co Ltd
- 28th July 1995
- 18th May 1999
- 1st April 2003
- 29th May 2000
- Eisai
- 28th November 1994
- 2nd January 2003
- 28th September 2005
- Esperion Therapeutics Inc
- Gene Logic Inc
- 4th October 2001
- 21st December 2001
- 27th September 2005
- Genentech Inc
- Helsinn Healthcare SA
- Immunicon Corporation
- 21st December 2004
- 28th March 2006
- Incyte Corporation
- Inpharmatica Ltd
- Isis Pharmaceuticals Inc
- 27th March 2002
- 22nd January 2003
- 24th May 2005
- Japan Tobacco Inc
- February 1994
- 23rd June 1998
- Ligand Pharmaceuticals Inc
- 1st September 1999
- 23rd December 1999
- 26th September 2000
- 6th March 2002
- 9th November 2004
- 3rd February 2005
- Medarex Inc
- 16th April 2003
- 20th September 2004
- Merck & Co
- Nektar Therapeutics
- January 1995
- October 1996
- December 1999
- 26th January 2001
- 14th October 2002
- 1st March 2006
- Neurocrine Biosciences Inc
- 19th December 2002
- 16th June 2005
- Neurogen Corporation
- GABA agreement
- July 1994
- 4th January 2001
- 31st December 2004
- AIDD agreement
- 17th June 1999
- NPY agreement
- 12th May 1999
- NicOx SA
- 26th August 2004
- 21st July 2005
- Nicholas Piramal India Ltd
- Noxxon Pharma AG
- Onyx Pharmaceuticals Inc
- OSI Pharmaceuticals Inc/New York University
- 19th June 2000
- 26th November 2001
- 17th July 2002
- 18th December 2002
- 22nd April 2003
- Oscient Pharmaceuticals Corporation
- 7th February 2006
- 8th February 2006
- Oxford BioMedica plc (OBM)
- Recordati
- Renovis Inc
- Rigel Pharmaceuticals Inc
- 25th January 2001
- 28th November 2001
- 6th May 2002
- 20th January 2005
- Schering AG
- Schwarz Pharma AG
- Serono
- SkyePharma plc
- Others
- Discontinued Agreements
APPENDIX 4 - INFRASTRUCTURE
- Manufacturing Facilities
- Pfizer's Major Manufacturing Sites
- Plant Rationalisation
- Plant Divestitures
- Plant Expansions/New Projects
- R&D Facilities
APPENDIX 5 - Key PHARMACEUTICAL
- SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint-Venture Companies
APPENDIX 6 - PRODUCT INDEX
|
